BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) and NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.
Institutional & Insider Ownership
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations for BioMarin Pharmaceutical and NeuroBo Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioMarin Pharmaceutical | 0 | 7 | 17 | 0 | 2.71 |
| NeuroBo Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares BioMarin Pharmaceutical and NeuroBo Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioMarin Pharmaceutical | 14.96% | 9.91% | 7.65% |
| NeuroBo Pharmaceuticals | N/A | -189.12% | -122.31% |
Volatility and Risk
BioMarin Pharmaceutical has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioMarin Pharmaceutical and NeuroBo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioMarin Pharmaceutical | $2.85 billion | 3.80 | $167.65 million | $2.20 | 25.83 |
| NeuroBo Pharmaceuticals | N/A | N/A | -$12.47 million | N/A | N/A |
BioMarin Pharmaceutical has higher revenue and earnings than NeuroBo Pharmaceuticals.
Summary
BioMarin Pharmaceutical beats NeuroBo Pharmaceuticals on 9 of the 11 factors compared between the two stocks.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
